Get all your news in one place.
100's of premium titles.
One app.
Start reading
Evening Standard
Evening Standard
Henry Saker-Clark

GSK posts higher profits but indicates sales growth to slow in 2026

GSK has agreed to buy a pharmaceutical firm that is developing treatment for people with food allergies (GSK/PA) -

Pharmaceutical giant GSK has revealed a jump in profits amid a boost from HIV and asthma treatments, but pointed towards slower growth next year.

It came amid the first set of results by new chief executive Luke Miels, who took over from Emma Walmsley at the turn of the year.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.